Drug Profile
Research programme: toll-like receptor 7 modulators - Telormedix
Alternative Names: TMX-202; TMX-302; TMX-30XLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Foamix; Telormedix; University of California, San Diego
- Class Small molecules
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 7 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Skin cancer
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-cancer in Germany (Topical, Foam)